Learning to Turn Down Your Amygdala Can Modify Your Emotions
Reports new study in Biological Psychiatry
Reports new study in Biological Psychiatry
Training the brain to treat itself is a promising therapy for traumatic stress. The training uses an auditory or visual signal that corresponds to the activity of a particular brain region, called neurofeedback, which can guide people to regulate their own brain activity.
However, treating stress-related disorders requires accessing the brain’s emotional hub, the amygdala, which is located deep in the brain and difficult to reach with typical neurofeedback methods. This type of activity has typically only been measured using functional magnetic resonance imaging (fMRI), which is costly and poorly accessible, limiting its clinical use.
A study published in the current issue of Biological Psychiatry tested a new imaging method that provided reliable neurofeedback on the level of amygdala activity using electroencephalography (EEG), and allowed people to alter their own emotional responses through self-regulation of its activity.
“The major advancement of this new tool is the ability to use a low-cost and accessible imaging method such as EEG to depict deeply located brain activity,” said both senior author Dr. Talma Hendler of Tel-Aviv University in Israel and The Sagol Brain Center at Tel Aviv Sourasky Medical Center, and first author Jackob Keynan, a PhD student in Hendler’s laboratory, in an email to Biological Psychiatry.
The researchers built upon a new imaging tool they had developed in a previous study that uses EEG to measure changes in amygdala activity, indicated by its “electrical fingerprint”. With the new tool, 42 participants were trained to reduce an auditory feedback corresponding to their amygdala activity using any mental strategies they found effective.
During this neurofeedback task, the participants learned to modulate their own amygdala electrical activity. This also led to improved downregulation of blood-oxygen level dependent signals of the amygdala, an indicator of regional activation measured with fMRI.
In another experiment with 40 participants, the researchers showed that learning to downregulate amygdala activity could actually improve behavioral emotion regulation. They showed this using a behavioral task invoking emotional processing in the amygdala. The findings show that with this new imaging tool, people can modify both the neural processes and behavioral manifestations of their emotions.
“We have long known that there might be ways to tune down the amygdala through biofeedback, meditation, or even the effects of placebos,” said John Krystal, Editor of Biological Psychiatry. “It is an exciting idea that perhaps direct feedback on the level of activity of the amygdala can be used to help people gain control of their emotional responses.”
The participants in the study were healthy, so the tool still needs to be tested in the context of real-life trauma. However, according to the authors, this new method has huge clinical implications.
The approach “holds the promise of reaching anyone anywhere,” said Hendler and Keynan. The mobility and low cost of EEG contribute to its potential for a home-stationed bedside treatment for recent trauma patients or for stress resilience training for people prone to trauma.
Notes for editors
The article is "Limbic Activity Modulation Guided by Functional Magnetic Resonance Imaging–Inspired Electroencephalography Improves Implicit Emotion Regulation," by Jackob N. Keynan, Yehudit Meir-Hasson, Gadi Gilam, Avihay Cohen, Gilan Jackont, Sivan Kinreich, Limor Ikar, Ayelet Or-Borichev, Amit Etkin, Anett Gyurak, Ilana Klovatch, Nathan Intrator, and Talma Hendler (doi:10.1016/j.biopsych.2015.12.024). It appears in Biological Psychiatry, volume 80, issue 6 (2016), published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 214 648 0880 or email@example.com. Journalists wishing to interview the authors may contact Talma Hendler at firstname.lastname@example.org.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 140 Psychiatry titles and 11th out of 256 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2015 Impact Factor score for Biological Psychiatry is 11.212.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com